Exelixis, Inc.
EXEL
Ранг среди акций
#1383
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Цена акции
$64.01
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$16.09B
Изменение (1 день)
2.11%
Изменение (1 год)
77.15%
Страна
US
Торговля Exelixis, Inc. (EXEL)
Категория
Healthcare
Коэффициент P/E для Exelixis, Inc. (EXEL)
Коэффициент P/E на October 2026 TTM: 18.54
Согласно последним финансовым отчетам и цене акций Exelixis, Inc., текущий P/E (TTM) составляет 18.54. В конце 2025 у компании был P/E на уровне 18.90.
История P/E компании Exelixis, Inc. с 2000 по 2026
P/E на конец каждого года
| Год | P/E коэффициент | Изменить |
|---|---|---|
| 2026 (TTM) | 18.54 | -1.92% |
| 2025 | 18.90 | -48.55% |
| 2023 | 36.74 | 29.84% |
| 2022 | 28.29 | 13.57% |
| 2021 | 24.91 | 55.37% |
| 2020 | 16.03 | 91.06% |
| 2018 | 8.39 | -85.50% |
| 2017 | 57.87 | -208.79% |
| 2016 | -53.19 | 5,005.52% |
| 2014 | -1.04 | -77.39% |
| 2013 | -4.61 | -5.78% |
| 2012 | -4.89 | -162.05% |
| 2011 | 7.88 | -181.69% |
| 2010 | -9.65 | 185.36% |
| 2009 | -3.38 | -66.78% |
| 2007 | -10.18 | 32.57% |
| 2006 | -7.68 | -12.69% |
| 2005 | -8.80 | 75.26% |
| 2004 | -5.02 | 3.18% |
| 2003 | -4.86 | -7.50% |
| 2002 | -5.26 | -51.55% |
| 2001 | -10.85 | 80.10% |
| 2000 | -6.03 | 0.00% |
P/E для схожих компаний или конкурентов
| Компания | P/E Ratio | Разница P/E | Страна |
|---|---|---|---|
| 28.78 | 55.26% |
US
|
|
| -28.36 | -252.97% |
US
|
|
| -24.57 | -232.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 63.61% |
NL
|
Как читать P/E Ratio?
Коэффициент цена/прибыль (P/E Ratio) отражает соотношение между ценой акции компании и её прибылью на акцию.
Низкий, но положительный P/E говорит о том, что компания приносит высокую прибыль при низкой оценке и может быть недооценена. Высокий отрицательный (близкий к 0) P/E указывает на значительные убытки.
Компании с P/E выше 30 или отрицательным считаются "акциями роста" — инвесторы ожидают роста или будущей прибыли.
Компании с положительным P/E ниже 10 считаются "ценностными акциями", т.е. уже прибыльны, но с низким потенциалом роста.